Ekso Bionics Q2 revenue falls 58% YoY to $2.1M; net loss $2.7M

EKSO BIONICS HOLDINGS, INC.

2025-Q2 EPS reported -$3.01 revenue$5,432,000

Revenue $2.1M vs $5.0M in Q2 2024, down 58% due to lower Enterprise Health device sales.
Gross margin 40% vs 53% prior year; gross profit $0.8M vs $2.6M.
Net loss $2.7M ($1.24/share) vs $2.4M ($1.99/share) in Q2 2024.
Personal Health device sales grew >50% YoY in H1 2025; cash $5.2M at June 30.
Named Bionic P&O as first Ekso Indego Personal distributor; joined NVIDIA Connect program.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.